SlideShare a Scribd company logo
Salt restriction
Jim Ritchie
What do we tell patients
?
Background
CKD
Impaired sodium
excretion
Increased
BP
Resistance
to RAAS
blockade
Glomerular hyper-
filtration
Increased
proteinuria
Current guidelines
Smyth et al. Am J Hyertens 2014 epub ahead of print
Current guidelines
• Lower sodium intake to
<90mmol / day (5g salt)
• Advice appropriate to the
stage of CKD (CG182)
• CG127 - Restrict / limit
dietary sodium
• Public health UK:<6g / day
(2015); <3g / day (2025)
Blood pressure effect
(CG127)
Unclear if benefits sustained beyond 12 months
Cochrane 2014
Relative risk 95% CI
Mortality 1.00 0.86 - 1.15
CV mortality 0.67 0.45 - 1.01
CV events 0.76 0.57 - 1.01
Change in SBP -1.79 -3.23 - -0.26
Change in urinary
Na excretion
-20 -53 - 12
Progression of CKD
Smyth et al. Am J Hyertens 2014 epub ahead of print
Author Year Comparison Summary
Cianciaruso 1998
>4.6 (5.3) vs. <2.3 (1.9)
g / day sodium
Mean decline CrCl
0.51±0.09 vs. 0.25±0.07
Amaha 2010
Correlation of intake vs.
eGFR decline
r= -0.29
Vegter 2011
<2.9 / 2.9 - 5.8 / >5.8 g
/day
HR ESRD:
High vs. low 3.3
(1.7 - 6.4)
Medium vs. low 1.4
(0.8 - 2.3)
Lambers 2012
<3.5 / 3.5 - 4.8 / >4.8 g /
day
HR Cr x2
Low vs. high 0.75
(0.53 - 1.05)
Data do not support strict Na restriction
Progression of proteinuria
Author Year Comparison Summary
Cianciaruso 1998
>4.6 (5.3) vs. <2.3 (1.9)
g / day sodium
~ 1 g / 24 hour increase
vs. ~1g / 24 hour
decrease.
Amaha 2010
Correlation of intake vs.
proteinuria
r = 0.53
Vegter 2011
<2.9 / 2.9 - 5.8 / >5.8 g
/day
31 / 25 / 20% reduction
in proteinuria
(p for trend = 0.012)
Lambers 2012
<3.5 / 3.5 - 4.8 / >4.8 g /
day
uACR reduction
44 / 16 / 21 mg/g
Smyth et al. Am J Hyertens 2014 epub ahead of print
Uncertainties
Assumption of linear effect
between reduction in sodium
intake and improved renal
outcomes.
Will blood pressure reductions
lead to proportionately slower
renal functional loss (BP agent
class effects)
Salt sensitivity / retention / BP
dipping patterns in CKD not
considered
Uncertainties
Data linked to CV
outcomes are J-shaped
O’Donnell et al. JAMA 2011(23);306
Retrospective study of
305 PD patients (patient
reported dietary
information); HR death /
1 g/day increase in Na
0.44 (0.2 - 0.9) p=0.04
Dong et al. cJASN 2010(5);240-7
< 3 g/day Na linked with RAAS
activation…
Yoshioka et al. Circ Res 1987(61);531-8
Recent data
• JASN 2014 - LowSALT CKD study (n=20)
• BMJ 2011 - HONEST study (n=52)
• KI 2014 - ONTARGET / TRANSCEND (n=29,000)
LowSALT
• n=20. 1 week run in.
• Counselled to low sodium diet (60 - 80 mmol/day). Then
crossover period of 120 mmol Na tablet / placebo (2
weeks / 1 week / 2 weeks)
• Age = 69; CKD 3-4 ; proteinuria = 0.5 g/24hours
• Blood pressure 151 / 82 mmHg (3 agents)
• 30% angiotensin blockade; 40% diuretic (4 patients
changed medications during study period)
McMahon et al. JASN 2014. ePub ahead of print
Blood pressure effects
Squares - high salt period; triangles low salt period
McMahon et al. JASN 2014. ePub ahead of print
Proteinuria
r = -0.1; p = 0.69
McMahon et al. JASN 2014. ePub ahead of print
HONEST
• Non-diabetic CKD (n=52)
• Mean age = 52; BMI 28; eGFR ~44 ml/min/1.73m2
• Blood pressure >125 / 75 mmHg in spite of maximal
ACEi (135 / 78 mmHg)
• Residual proteinuria >1 g/24 hours
• Non-study drugs locked in (25% diuretic)
Slagman et al. BMJ 2011; Jul26 p343-344
HONEST
Slagman et al. BMJ 2011; Jul26 p343-344
6 WEEK RUN IN PERIOD
40 mg lisonopril
Placebo
A2 blockade
telmisartan 320mg
Low sodium
High sodium
4 x six week periods. No wash out
Low salt = 3g / 24 hours. High salt = 12.6g / 24 hours
Proteinuria
1.68 [1.3-2.1]
vs
1.44 [1.1-1.9]
0.86 [0.6-1.1]
vs
0.67 [0.5-0.9]
Other results
• Urinary sodium excretion 190 vs. 105 mmol/24
hours
• ~10 mmgHg reduction in systolic blood pressures
• Low salt: reduced odema; albumin 38 -> 40
• 10 umol/L increase in serum creatinine on low salt
diet (reversible)
• 0.1 mmol/L increase in serum potassium
ONTARGET /
TRANSCEND
• ONTARGET
• telmisartan / ramipril / combination in patients with
diabetes or vascular disease
• n=25,000
• TRANSCEND
• telmisartan / placebo (ACEi intolerant population)
• n=6000
Smyth et al. KI 2014(86) 1205-12
ONTARGET /
TRANSCEND
• Mean age 66; eGFR 68 (30% CKD 3+); angiotensin
blockade >90%
• 15% micro / macroalbuminuria
• Divided by urinary sodium excretion (<2; 2-4; 4-6; 6-
8; >8)
• 56 months follow-up
Smyth et al. KI 2014(86) 1205-12
Renal outcomes
Smyth et al. KI 2014(86) 1205-12
Low sodium
3.3g
Moderate
4.7g
High
6.2g
eGFR increase
>30% / RRT
1 0.98 [0.92-1.04] 0.99 [0.89-1.09]
Doubling sCr 1 0.96 [0.84-1.11] 0.94 [0.75-1.19]
Progression of
proteinuria
1 0.96 [0.91-1.02] 0.92 [0.84-1.01]
Hyperkalaemia 1 1.08 [0.98-1.19] 1.09 [0.93-1.28]
Renal outcomes
Smyth et al. KI 2014(86) 1205-12
>30% eGFR reduction
Progression between
stages of albuminuria
Potassium
Smyth et al. KI 2014(86) 1205-12
>30% eGFR reduction
Progression between
stages of albuminuria
Potassium
• Reduces renal vascular resistance and increases renal
blood flow
• Found in “positive’ foods; association with antioxidants
• In rat models, up-regulates kinins which protect from
fibrosis
• Association lost in CKD 3b / 4
• possible confounding (i.e. more advanced CKD may
have had more limited potassium intake)
Smyth et al. KI 2014(86) 1205-12
Conclusions
• Sodium restriction likely of benefit but hard to
quantify
• Consideration of patient specific data e.g. nephrosis
• Dietary advice may be dynamic over continuum of
CKD

More Related Content

What's hot

Advance Results
Advance ResultsAdvance Results
Advance Results
Rodolfo Rafael
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
MedicineAndHealthUSA
 
Diabetic kidney disease
Diabetic kidney diseaseDiabetic kidney disease
Diabetic kidney disease
Joel Topf
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
Dr Vivek Baliga
 
ACCORD Trial_Review
ACCORD Trial_ReviewACCORD Trial_Review
ACCORD Trial_Review
dhavalshah4424
 
Cvd risk in dm
Cvd risk in dmCvd risk in dm
Cvd risk in dm
Naveen Kumar
 
Dkd new look
Dkd new lookDkd new look
Dkd new look
Muhamed Al Rohani
 
Case study hypertension presentation show
Case study  hypertension presentation showCase study  hypertension presentation show
Case study hypertension presentation show
Kern Rocke
 
1100323-糖尿病的治療要更重視心腎的合併症
1100323-糖尿病的治療要更重視心腎的合併症1100323-糖尿病的治療要更重視心腎的合併症
1100323-糖尿病的治療要更重視心腎的合併症
Ks doctor
 
Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)
Christos Argyropoulos
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Results
theheart.org
 
Advance Design
Advance DesignAdvance Design
Advance Design
hospital
 
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadDrug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
NephroTube - Dr.Gawad
 
Diabetes and the kidneys
Diabetes and the kidneysDiabetes and the kidneys
Diabetes and the kidneys
Umi Khoirun
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney Disease
Christos Argyropoulos
 
New uric acid disorder
New uric acid disorderNew uric acid disorder
New uric acid disorder
Dr. Lalit Agarwal
 
SGLT2i & T2DM final by prof. taj jamshad
SGLT2i & T2DM final by prof. taj jamshadSGLT2i & T2DM final by prof. taj jamshad
SGLT2i & T2DM final by prof. taj jamshad
TAJ JAMSHAD
 
Prescribing an app
Prescribing an appPrescribing an app
Prescribing an app
Joel Topf
 
CKD Reclassification 2016
CKD Reclassification 2016CKD Reclassification 2016
CKD Reclassification 2016
Meguid Nahas
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about it
Christos Argyropoulos
 

What's hot (20)

Advance Results
Advance ResultsAdvance Results
Advance Results
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
 
Diabetic kidney disease
Diabetic kidney diseaseDiabetic kidney disease
Diabetic kidney disease
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
 
ACCORD Trial_Review
ACCORD Trial_ReviewACCORD Trial_Review
ACCORD Trial_Review
 
Cvd risk in dm
Cvd risk in dmCvd risk in dm
Cvd risk in dm
 
Dkd new look
Dkd new lookDkd new look
Dkd new look
 
Case study hypertension presentation show
Case study  hypertension presentation showCase study  hypertension presentation show
Case study hypertension presentation show
 
1100323-糖尿病的治療要更重視心腎的合併症
1100323-糖尿病的治療要更重視心腎的合併症1100323-糖尿病的治療要更重視心腎的合併症
1100323-糖尿病的治療要更重視心腎的合併症
 
Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)Update on Diabetic Nephropathy (2018)
Update on Diabetic Nephropathy (2018)
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Results
 
Advance Design
Advance DesignAdvance Design
Advance Design
 
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadDrug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
 
Diabetes and the kidneys
Diabetes and the kidneysDiabetes and the kidneys
Diabetes and the kidneys
 
ASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney DiseaseASK1 Inhibition in Diabetic Kidney Disease
ASK1 Inhibition in Diabetic Kidney Disease
 
New uric acid disorder
New uric acid disorderNew uric acid disorder
New uric acid disorder
 
SGLT2i & T2DM final by prof. taj jamshad
SGLT2i & T2DM final by prof. taj jamshadSGLT2i & T2DM final by prof. taj jamshad
SGLT2i & T2DM final by prof. taj jamshad
 
Prescribing an app
Prescribing an appPrescribing an app
Prescribing an app
 
CKD Reclassification 2016
CKD Reclassification 2016CKD Reclassification 2016
CKD Reclassification 2016
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about it
 

Similar to Salt intake in renal disease

Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?
Dr Vivek Baliga
 
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Dr Vivek Baliga
 
Timing for initiation of dialysis.
Timing for initiation of dialysis.Timing for initiation of dialysis.
Timing for initiation of dialysis.
Dr. Lalit Agarwal
 
AKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxAKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptx
DrHarsh Saxena
 
SGLT 2 inhibitors
SGLT 2 inhibitorsSGLT 2 inhibitors
SGLT 2 inhibitors
Naveen Kumar
 
Gliclazide in DKD - Case Study.pptx
Gliclazide in DKD - Case Study.pptxGliclazide in DKD - Case Study.pptx
Gliclazide in DKD - Case Study.pptx
AmeetRathod3
 
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
cacao83
 
Glitazonas e idpp 4 2016
Glitazonas  e idpp 4 2016Glitazonas  e idpp 4 2016
Glitazonas e idpp 4 2016
Facultad de Medicina. UNIDA. Paraguay
 
Ckd 2016 100 2
Ckd 2016 100 2Ckd 2016 100 2
Ckd 2016 100 2
FarragBahbah
 
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 InhibitorA Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
DerekRuzzo
 
Ckd pre dialysis management
Ckd pre dialysis managementCkd pre dialysis management
Ckd pre dialysis management
Shruthi Kodad
 
best Ckd presentation1 by Dr. sachin kr rana
best Ckd presentation1  by Dr. sachin kr ranabest Ckd presentation1  by Dr. sachin kr rana
best Ckd presentation1 by Dr. sachin kr rana
Sachin Rana
 
the advance on Strategy to optimally achieve blood glucose control
the advance on Strategy to optimally achieve blood glucose controlthe advance on Strategy to optimally achieve blood glucose control
the advance on Strategy to optimally achieve blood glucose control
januar arifin
 
Gastrocon 2016 - Hepatorenal Syndrome
Gastrocon 2016 - Hepatorenal SyndromeGastrocon 2016 - Hepatorenal Syndrome
Gastrocon 2016 - Hepatorenal Syndrome
ApolloGleaneagls
 
Saxagliptin Diabetes DPP4 evidences & Trials
Saxagliptin Diabetes DPP4 evidences & TrialsSaxagliptin Diabetes DPP4 evidences & Trials
Saxagliptin Diabetes DPP4 evidences & Trials
AmitSaha472186
 
EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...
EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...
EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...
Yogacharya AB Bhavanani
 
Anemia wi
Anemia wiAnemia wi
CKD Presentation PDF
CKD Presentation PDFCKD Presentation PDF
CKD Presentation PDF
Patwant Dhillon
 
New in Type 2 Diabetes Mellitus
New in Type 2 Diabetes MellitusNew in Type 2 Diabetes Mellitus
New in Type 2 Diabetes Mellitus
gauravpalikhe1980
 
Avances en Insulinoterapia Dr Paz 2014
Avances en Insulinoterapia Dr Paz 2014Avances en Insulinoterapia Dr Paz 2014
Avances en Insulinoterapia Dr Paz 2014
JOSE LUIS PAZ IBARRA
 

Similar to Salt intake in renal disease (20)

Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?
 
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough Atorvastatin:  Statins in CVD management.  Is just lipid lowering enough
Atorvastatin:  Statins in CVD management. Is just lipid lowering enough
 
Timing for initiation of dialysis.
Timing for initiation of dialysis.Timing for initiation of dialysis.
Timing for initiation of dialysis.
 
AKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptxAKI IN CIRRHOSIS 1.pptx
AKI IN CIRRHOSIS 1.pptx
 
SGLT 2 inhibitors
SGLT 2 inhibitorsSGLT 2 inhibitors
SGLT 2 inhibitors
 
Gliclazide in DKD - Case Study.pptx
Gliclazide in DKD - Case Study.pptxGliclazide in DKD - Case Study.pptx
Gliclazide in DKD - Case Study.pptx
 
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
 
Glitazonas e idpp 4 2016
Glitazonas  e idpp 4 2016Glitazonas  e idpp 4 2016
Glitazonas e idpp 4 2016
 
Ckd 2016 100 2
Ckd 2016 100 2Ckd 2016 100 2
Ckd 2016 100 2
 
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 InhibitorA Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
A Comparison of an Oral GLP-1 Receptor Antagonist and SGLT2 Inhibitor
 
Ckd pre dialysis management
Ckd pre dialysis managementCkd pre dialysis management
Ckd pre dialysis management
 
best Ckd presentation1 by Dr. sachin kr rana
best Ckd presentation1  by Dr. sachin kr ranabest Ckd presentation1  by Dr. sachin kr rana
best Ckd presentation1 by Dr. sachin kr rana
 
the advance on Strategy to optimally achieve blood glucose control
the advance on Strategy to optimally achieve blood glucose controlthe advance on Strategy to optimally achieve blood glucose control
the advance on Strategy to optimally achieve blood glucose control
 
Gastrocon 2016 - Hepatorenal Syndrome
Gastrocon 2016 - Hepatorenal SyndromeGastrocon 2016 - Hepatorenal Syndrome
Gastrocon 2016 - Hepatorenal Syndrome
 
Saxagliptin Diabetes DPP4 evidences & Trials
Saxagliptin Diabetes DPP4 evidences & TrialsSaxagliptin Diabetes DPP4 evidences & Trials
Saxagliptin Diabetes DPP4 evidences & Trials
 
EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...
EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...
EFFECT OF YOGA THERAPY ON REACTION TIME, BIOCHEMICAL PARAMETERS AND WELLNESS ...
 
Anemia wi
Anemia wiAnemia wi
Anemia wi
 
CKD Presentation PDF
CKD Presentation PDFCKD Presentation PDF
CKD Presentation PDF
 
New in Type 2 Diabetes Mellitus
New in Type 2 Diabetes MellitusNew in Type 2 Diabetes Mellitus
New in Type 2 Diabetes Mellitus
 
Avances en Insulinoterapia Dr Paz 2014
Avances en Insulinoterapia Dr Paz 2014Avances en Insulinoterapia Dr Paz 2014
Avances en Insulinoterapia Dr Paz 2014
 

Recently uploaded

Know Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdfKnow Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdf
Dr. Sujit Chatterjee CEO Hiranandani Hospital
 
FACIAL NERVE
FACIAL NERVEFACIAL NERVE
FACIAL NERVE
aditigupta1117
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DR Jag Mohan Prajapati
 
leprosy Case detection and diagnosis.pptx
leprosy Case detection and diagnosis.pptxleprosy Case detection and diagnosis.pptx
leprosy Case detection and diagnosis.pptx
habtegirma
 
Monopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in TripuraMonopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in Tripura
SKG Internationals
 
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Lighthouse Retreat
 
1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样
1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样
1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样
5sj7jxf7
 
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
gjsma0ep
 
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell
 
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
xkute
 
muscluskeletal assessment...........pptx
muscluskeletal assessment...........pptxmuscluskeletal assessment...........pptx
muscluskeletal assessment...........pptx
RushikeshHange1
 
Emotional and Behavioural Problems in Children - Counselling and Family Thera...
Emotional and Behavioural Problems in Children - Counselling and Family Thera...Emotional and Behavioural Problems in Children - Counselling and Family Thera...
Emotional and Behavioural Problems in Children - Counselling and Family Thera...
PsychoTech Services
 
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdfCHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
Sachin Sharma
 
Sexual Disorders.gender identity disorderspptx
Sexual Disorders.gender identity  disorderspptxSexual Disorders.gender identity  disorderspptx
Sexual Disorders.gender identity disorderspptx
Pupayumnam1
 
The Importance of Black Women Understanding the Chemicals in Their Personal C...
The Importance of Black Women Understanding the Chemicals in Their Personal C...The Importance of Black Women Understanding the Chemicals in Their Personal C...
The Importance of Black Women Understanding the Chemicals in Their Personal C...
bkling
 
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdfVEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
Vedanta A
 
Data-Driven Dispensing- Rise of AI in Pharmacies.pdf
Data-Driven Dispensing- Rise of AI in Pharmacies.pdfData-Driven Dispensing- Rise of AI in Pharmacies.pdf
Data-Driven Dispensing- Rise of AI in Pharmacies.pdf
Jasper Colin
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
priyabhojwani1200
 
GIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure andGIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure and
MuzafarBohio
 
Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.
Vishal kr Thakur
 

Recently uploaded (20)

Know Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdfKnow Latest Hiranandani Hospital Powai News.pdf
Know Latest Hiranandani Hospital Powai News.pdf
 
FACIAL NERVE
FACIAL NERVEFACIAL NERVE
FACIAL NERVE
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
 
leprosy Case detection and diagnosis.pptx
leprosy Case detection and diagnosis.pptxleprosy Case detection and diagnosis.pptx
leprosy Case detection and diagnosis.pptx
 
Monopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in TripuraMonopoly PCD Pharma Franchise in Tripura
Monopoly PCD Pharma Franchise in Tripura
 
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
 
1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样
1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样
1比1制作(uofm毕业证书)美国密歇根大学毕业证学位证书原版一模一样
 
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
 
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
 
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
一比一原版(UoA毕业证)昆士兰科技大学毕业证如何办理
 
muscluskeletal assessment...........pptx
muscluskeletal assessment...........pptxmuscluskeletal assessment...........pptx
muscluskeletal assessment...........pptx
 
Emotional and Behavioural Problems in Children - Counselling and Family Thera...
Emotional and Behavioural Problems in Children - Counselling and Family Thera...Emotional and Behavioural Problems in Children - Counselling and Family Thera...
Emotional and Behavioural Problems in Children - Counselling and Family Thera...
 
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdfCHAPTER 1 SEMESTER V  COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdf
 
Sexual Disorders.gender identity disorderspptx
Sexual Disorders.gender identity  disorderspptxSexual Disorders.gender identity  disorderspptx
Sexual Disorders.gender identity disorderspptx
 
The Importance of Black Women Understanding the Chemicals in Their Personal C...
The Importance of Black Women Understanding the Chemicals in Their Personal C...The Importance of Black Women Understanding the Chemicals in Their Personal C...
The Importance of Black Women Understanding the Chemicals in Their Personal C...
 
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdfVEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdf
 
Data-Driven Dispensing- Rise of AI in Pharmacies.pdf
Data-Driven Dispensing- Rise of AI in Pharmacies.pdfData-Driven Dispensing- Rise of AI in Pharmacies.pdf
Data-Driven Dispensing- Rise of AI in Pharmacies.pdf
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
 
GIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure andGIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure and
 
Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.Hypertension and it's role of physiotherapy in it.
Hypertension and it's role of physiotherapy in it.
 

Salt intake in renal disease

  • 2. What do we tell patients ?
  • 4. Current guidelines Smyth et al. Am J Hyertens 2014 epub ahead of print
  • 5. Current guidelines • Lower sodium intake to <90mmol / day (5g salt) • Advice appropriate to the stage of CKD (CG182) • CG127 - Restrict / limit dietary sodium • Public health UK:<6g / day (2015); <3g / day (2025)
  • 6. Blood pressure effect (CG127) Unclear if benefits sustained beyond 12 months
  • 7. Cochrane 2014 Relative risk 95% CI Mortality 1.00 0.86 - 1.15 CV mortality 0.67 0.45 - 1.01 CV events 0.76 0.57 - 1.01 Change in SBP -1.79 -3.23 - -0.26 Change in urinary Na excretion -20 -53 - 12
  • 8. Progression of CKD Smyth et al. Am J Hyertens 2014 epub ahead of print Author Year Comparison Summary Cianciaruso 1998 >4.6 (5.3) vs. <2.3 (1.9) g / day sodium Mean decline CrCl 0.51±0.09 vs. 0.25±0.07 Amaha 2010 Correlation of intake vs. eGFR decline r= -0.29 Vegter 2011 <2.9 / 2.9 - 5.8 / >5.8 g /day HR ESRD: High vs. low 3.3 (1.7 - 6.4) Medium vs. low 1.4 (0.8 - 2.3) Lambers 2012 <3.5 / 3.5 - 4.8 / >4.8 g / day HR Cr x2 Low vs. high 0.75 (0.53 - 1.05) Data do not support strict Na restriction
  • 9. Progression of proteinuria Author Year Comparison Summary Cianciaruso 1998 >4.6 (5.3) vs. <2.3 (1.9) g / day sodium ~ 1 g / 24 hour increase vs. ~1g / 24 hour decrease. Amaha 2010 Correlation of intake vs. proteinuria r = 0.53 Vegter 2011 <2.9 / 2.9 - 5.8 / >5.8 g /day 31 / 25 / 20% reduction in proteinuria (p for trend = 0.012) Lambers 2012 <3.5 / 3.5 - 4.8 / >4.8 g / day uACR reduction 44 / 16 / 21 mg/g Smyth et al. Am J Hyertens 2014 epub ahead of print
  • 10. Uncertainties Assumption of linear effect between reduction in sodium intake and improved renal outcomes. Will blood pressure reductions lead to proportionately slower renal functional loss (BP agent class effects) Salt sensitivity / retention / BP dipping patterns in CKD not considered
  • 11. Uncertainties Data linked to CV outcomes are J-shaped O’Donnell et al. JAMA 2011(23);306 Retrospective study of 305 PD patients (patient reported dietary information); HR death / 1 g/day increase in Na 0.44 (0.2 - 0.9) p=0.04 Dong et al. cJASN 2010(5);240-7 < 3 g/day Na linked with RAAS activation… Yoshioka et al. Circ Res 1987(61);531-8
  • 12. Recent data • JASN 2014 - LowSALT CKD study (n=20) • BMJ 2011 - HONEST study (n=52) • KI 2014 - ONTARGET / TRANSCEND (n=29,000)
  • 13. LowSALT • n=20. 1 week run in. • Counselled to low sodium diet (60 - 80 mmol/day). Then crossover period of 120 mmol Na tablet / placebo (2 weeks / 1 week / 2 weeks) • Age = 69; CKD 3-4 ; proteinuria = 0.5 g/24hours • Blood pressure 151 / 82 mmHg (3 agents) • 30% angiotensin blockade; 40% diuretic (4 patients changed medications during study period) McMahon et al. JASN 2014. ePub ahead of print
  • 14. Blood pressure effects Squares - high salt period; triangles low salt period McMahon et al. JASN 2014. ePub ahead of print
  • 15. Proteinuria r = -0.1; p = 0.69 McMahon et al. JASN 2014. ePub ahead of print
  • 16. HONEST • Non-diabetic CKD (n=52) • Mean age = 52; BMI 28; eGFR ~44 ml/min/1.73m2 • Blood pressure >125 / 75 mmHg in spite of maximal ACEi (135 / 78 mmHg) • Residual proteinuria >1 g/24 hours • Non-study drugs locked in (25% diuretic) Slagman et al. BMJ 2011; Jul26 p343-344
  • 17. HONEST Slagman et al. BMJ 2011; Jul26 p343-344 6 WEEK RUN IN PERIOD 40 mg lisonopril Placebo A2 blockade telmisartan 320mg Low sodium High sodium 4 x six week periods. No wash out Low salt = 3g / 24 hours. High salt = 12.6g / 24 hours
  • 19. Other results • Urinary sodium excretion 190 vs. 105 mmol/24 hours • ~10 mmgHg reduction in systolic blood pressures • Low salt: reduced odema; albumin 38 -> 40 • 10 umol/L increase in serum creatinine on low salt diet (reversible) • 0.1 mmol/L increase in serum potassium
  • 20. ONTARGET / TRANSCEND • ONTARGET • telmisartan / ramipril / combination in patients with diabetes or vascular disease • n=25,000 • TRANSCEND • telmisartan / placebo (ACEi intolerant population) • n=6000 Smyth et al. KI 2014(86) 1205-12
  • 21. ONTARGET / TRANSCEND • Mean age 66; eGFR 68 (30% CKD 3+); angiotensin blockade >90% • 15% micro / macroalbuminuria • Divided by urinary sodium excretion (<2; 2-4; 4-6; 6- 8; >8) • 56 months follow-up Smyth et al. KI 2014(86) 1205-12
  • 22. Renal outcomes Smyth et al. KI 2014(86) 1205-12 Low sodium 3.3g Moderate 4.7g High 6.2g eGFR increase >30% / RRT 1 0.98 [0.92-1.04] 0.99 [0.89-1.09] Doubling sCr 1 0.96 [0.84-1.11] 0.94 [0.75-1.19] Progression of proteinuria 1 0.96 [0.91-1.02] 0.92 [0.84-1.01] Hyperkalaemia 1 1.08 [0.98-1.19] 1.09 [0.93-1.28]
  • 23. Renal outcomes Smyth et al. KI 2014(86) 1205-12 >30% eGFR reduction Progression between stages of albuminuria
  • 24. Potassium Smyth et al. KI 2014(86) 1205-12 >30% eGFR reduction Progression between stages of albuminuria
  • 25. Potassium • Reduces renal vascular resistance and increases renal blood flow • Found in “positive’ foods; association with antioxidants • In rat models, up-regulates kinins which protect from fibrosis • Association lost in CKD 3b / 4 • possible confounding (i.e. more advanced CKD may have had more limited potassium intake) Smyth et al. KI 2014(86) 1205-12
  • 26. Conclusions • Sodium restriction likely of benefit but hard to quantify • Consideration of patient specific data e.g. nephrosis • Dietary advice may be dynamic over continuum of CKD